Silk Protein Microparticle-based Filler for Injection Augmentation
Safety and Efficacy of a Silk Protein Microparticle-based Filler for Injection Augmentation in Treating Unilateral Vocal Fold Paralysis
Sponsor: Sofregen Medical, Inc.
This NA trial investigates Dysphagia, Oropharyngeal and Dysphonia and is currently completed. Sofregen Medical, Inc. leads this study, which shows 9 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jun 2023 — Jul 2024 [monthly]
Completed NA
Status: Recruiting → Completed
-
Jan 2022 — Jun 2023 [monthly]
Recruiting NA
-
Feb 2021 — Jan 2022 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
▶ Show 4 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Not Yet Recruiting NA
-
Jul 2019 — Jan 2021 [monthly]
Not Yet Recruiting NA
-
May 2019 — Jul 2019 [monthly]
Not Yet Recruiting NA
-
Feb 2019 — May 2019 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Sofregen Medical, Inc.
- University of Southern California
For direct contact, visit the study record on ClinicalTrials.gov .